NPLB noted that including factors, such as diminishing returns and dynamic pricing, helps assess medication value better than traditional CEA.
No Patient Left Behind’s updated methodology accounts for disease severity, loss of market exclusivity and social value
Biopharma CEOs, investors call for same timeline for biologics, small molecules and lower out-of-pocket costs
Governments around the world have withheld access to life-changing medications for people with cystic fibrosis (CF) for years in the name of being hawkish on drug pricing.
Alzheimer’s and diseases like it have horrible costs on individuals, caregivers, and their families. A treatment for Alzheimer’s would not only relieve suffering for the patient and their family, but it would increase the productivity of millions of Americans and lower direct and indirect costs associated with care. And, once the treatment becomes generic, it will permanently upgrade human health for much less.
